奥美罗斯制药

Omeros Corp earns a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 33% discount to our quantitative fair value estimate of $27.78 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's valuation metrics bolster our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's price to cash ratio of 10.1 ranks in the top 45% compared with peers globally. While the liquidation value can be important for some businesses, we don't believe this is one of them. The low cash balance relative to the firm's market value could signal heavy reinvestment for growth. We believe this is a sign that shares could be undervalued.

Alternatively, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -3.6%, for example, falls in the bottom 20% compared with global peers. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.